Exchange: NASDAQ·Updated 07:34 PM EDT
BNTX logo

BNTXBioNTech SE - ADR

$92.33
$0.17
(0.18%)
Today
Closed $92.33
$0.00
(0.00%)
After Hours
EarningsAug 4
Mkt Cap$23.35B
Vol696,992.00
News
all
press releases
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
Zacks
More News
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.
Stocktwits
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.
Zacks
The New Cancer Moonshot: Innovative Companies Pursuing Game-Changing Therapies
Cancer treatment is undergoing one of the most significant transformations in modern medical history.
24-7 Market News
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Zacks
Investors Are Watching This High-Stakes Corner of Biotech
The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX
24-7 Market News
The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers
Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX
24-7 Market News
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
Zacks
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.
Zacks
<
1
2
...
>

Advertisement|Remove ads.